Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19

“…Recipients of solid organ transplants are known to be vulnerable to viral infections secondary to a weakened T‐cell mediated immune response 86 . From 10 case reports 87–96 and 10 case series, 25,97–105 we identified 66 COVID‐19 patients who received a solid organ transplant and who were treated with convalescent plasma. Of these 66 patients, mortality was observed in nine patients (14%), 4 patients remain hospitalized at the end of the observation period, and 25 patients demonstrated rapid improvement in clinical symptomatology.…”

Section: Secondary Immunodeficiencymentioning

confidence: 99%

Use of convalescent plasma inCOVID‐19 patients with immunosuppression

et al. 2021

View full text Add to dashboard Cite

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID‐19), including among patients with innate or acquired immunosuppression. However, the association between COVID‐19‐associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched‐control registry study of 143 COVID‐19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID‐19 patients with immunosuppression. We review clinical features and treatment protocols of COVID‐19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID‐19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune‐deficient and immune‐suppressed patients with COVID‐19 warrants further investigation.

show abstract

“…However, sample sizes for these different studies remain a strong limitation to the studies. Clinical trials in India involving 235 patients have been associated with limited success [ 186 ]; however, there is a potential benefit that would be associated with CPT therapy especially amongst COVID-19 patients with impaired immune function due to B-cell [ 187 ]. CPT continues to be important in older adult patients with symptomatic COVID-19 [ 188 ], and more studies emphasizing the immune response in these patients would yield a further understanding and knowledge for the promotion of medicine in this field.…”

Section: Covid-19 Convalescent Plasma (Ccp)mentioning

confidence: 99%

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Moubarak

Kasozi

Hetta

et al. 2021

Life

View full text Add to dashboard Cite

Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.

show abstract

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19

Cited by 49 publications

References 5 publications

Clinimetrics: Core Outcome Set for trials with Coronavirus disease 2019 (COVID-19-COS)

Clinimetrics: Core Outcome Set for trials with Coronavirus disease 2019 (COVID-19-COS)

Use of convalescent plasma inCOVID‐19 patients with immunosuppression

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Contact Info

Product

Resources

About